SnapShot: Brain-targeting anti-obesity medications

Jonas Petersen; Valdemar Brimnes Ingemann Johansen; Christoffer Clemmensen

doi:10.1016/j.cmet.2025.02.006

SnapShot: Brain-targeting anti-obesity medications

Cell Metab. 2025 Mar 4;37(3):790-790.e1. doi: 10.1016/j.cmet.2025.02.006.

Authors

Jonas Petersen¹, Valdemar Brimnes Ingemann Johansen¹, Christoffer Clemmensen²

Affiliations

¹ Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
² Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Electronic address: chc@sund.ku.dk.

PMID: 40043693
DOI: 10.1016/j.cmet.2025.02.006

Abstract

Advances in the understanding of homeostatic regulation of body weight and the neurobiology of appetite, combined with innovations in medicinal chemistry, have paved the way for safe and effective weight loss medications. Long-acting GLP-1 receptor agonists have revolutionized obesity treatment, and, together with emerging GLP-1-based multi-agonists and combination therapies, offer significant potential to combat cardiometabolic diseases and a range of other chronic health challenges. To view this SnapShot, open or download the PDF.

MeSH terms

Animals
Anti-Obesity Agents* / pharmacology
Anti-Obesity Agents* / therapeutic use
Brain* / drug effects
Brain* / metabolism
Glucagon-Like Peptide 1 / metabolism
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Obesity* / drug therapy
Obesity* / metabolism

Substances

Anti-Obesity Agents
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptide 1